Piramal Critical Care

Piramal Critical Care is a global pharmaceutical company delivering critical care solutions to patients and healthcare providers across more than 100 countries, with significant operations in the United States and Europe. The company maintains a comprehensive product portfolio spanning inhalation anesthetics, intrathecal therapies for spasticity ma... nagement, injectable pain and anesthesia medications, injectable anti-infectives, oral treatments for rare genetic disorders including Type I Gaucher and Niemann Pick Type C disease, anticholinergic agents, and plasma volume expanders. Key branded products include Sevoflurane, Desflurane, Isoflurane, and Halothane for inhalation anesthesia; Gablofen (Baclofen Injection), MITIGO (Morphine Sulfate), Dipidolor (Piritramide), Sublimaze (Fentanyl Citrate), Rapifen (Alfentanil Hydrochloride), Sufenta (Sufentanil Citrate), and Hypnomidate (Etomidate) for injectable pain and anesthesia; a broad range of injectable anti-infectives including Ampicillin and Sulbactam, Cefepime, Ceftriaxone, Oxacillin, Linezolid, Piperacillin and Tazobactam; Yargesa (Miglustat) for rare disease management; Glycopyrrolate Injection; and Haemaccel for plasma volume expansion. Piramal Critical Care entered the inhalation anesthetics market in 2002 through the acquisition of ICI India Ltd. and has since expanded through strategic acquisitions, including a recent acquisition of Janssen pharmaceutical brands and related intellectual property covering both active pharmaceutical ingredients and finished dosage forms, as well as a portfolio of intrathecal spasticity and pain management drugs from Mallinckrodt LLC. The company's growth strategy emphasizes building successful partnerships and expanding its hospital pharmaceutical product offerings while increasing market share of existing products, positioning Piramal Critical Care as a diversified critical care pharmaceutical provider serving global healthcare systems.Read More